AUA Annual Meeting Highlights (2019): Prostate Cancer

To better understand urologists’ educational needs for treating CRPC, the AUA conducted an in-depth educational needs assessment of its domestic membership representing >90% of U.S. Board Certified urologists in 2013 (Phase I). The AUA reassessed its member’s educational needs after releasing the updated CRPC Guideline and targeted CRPC educational activities in 2015 (Phase II) and again in 2017 (Phase III). Areas identified as an educational need with regard to managing CRPC patients center on sequencing of agents, managing side effects of treatments, management of comorbid conditions and identifying potential interactions between immunosuppressive agents and other medications. Urologists continue to indicate a strong educational need for a thorough review of the AUA CRPC Guideline.

Target Audience

  • Urologists
  • Urologists in training
  • Non-physician providers involved in urology

Learning Objectives

013IC: Genetic testing in prostate cancer: Understanding clinical implications for early detection, localized disease, and CRPC

At the conclusion of this CME activity, participants should be able to:

  • Counsel men with BRCA1/2 mutations, Lynch syndrome, and other key inherited syndromes regarding their prostate cancer risk and appropriate strategies for cancer screening.
  • Identify the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.
  • Interpret results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.
  • Utilize the results of genetic testing to improve outcomes among patients with metastatic prostate cancer, including recommendations regarding PARP-inhibition, chemotherapy, and immunotherapy.

 

Course 027IC: AUA CRPC Guidelines and Therapeutic Advances in Metastatic Prostate Cancer

At the conclusion of this CME activity, participants should be able to:

  • Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC.
  • Explain the sequencing and indications for active treatment with approved agents in the management of nmCRPC.
  • Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines.
  • Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice.
  • Describe breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer.

 

Course 037IC: Using Shared Decision Making to Help Patients Decide on Prostate Cancer Screening and Treatment

At the conclusion of this CME activity, participants should be able to:

  • Explain Shared Decision Making.
  • Discuss the impact of shared decision making on patients and on patient-clinician communication.
  • Describe at least one implementation strategy for using shared decision making in clinical practice.

 

Course 048IC: Novel Agents and Concepts in the Management of Hormone Naïve and CRPC

At the conclusion of this CME activity, participants should be able to:

  • Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and outline the treatments and the proper order for administration.
  • Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and counsel patients on the pros and cons of therapy.
  • Analyze the mechanism of action and risks/benefits of using systemic agents in the treatment of nm/mCRPC.
  • Describe the bone-targeted, radiopharmaceutical agent and its sequencing.
  • Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC.

 

Course 065IC: Prostate Cancer Update

At the conclusion of this CME activity, participants should be able to:

  • Cite important new publications in this field during the past year.
  • Identify the relative strengths and weaknesses of the reports.
  • Evaluate how new studies relate to the existing state-of-the-art in clinical practice.
  • Analyze whether they and their colleagues should consider changing their practice based on the new information.

 

 

Course summary
Available credit: 
  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation
Course opens: 
10/01/2019
Course expires: 
10/31/2020
Rating: 
0

013IC: Genetic testing in prostate cancer: Understanding clinical implications for early detection, localized disease, and CRPC

Todd M. Morgan, MD, Course Director

Associate Professor of Urology

University of Michigan

Ann Arbor, MI

Disclosures: Visible Health, Inc: Leadership Position, Owner, Product Development; Myriad Genetics: Scientific Study or Trial; GenomeDx: Scientific Study or Trial

 

Leonard G. Gomella, MD, FACS

Bernard W. Godwin, Jr. Professor of Prostate Cancer

Chairman of the Department of Urology

Sidney Kimmel Medical College at Thomas Jefferson University

Philadelphia, PA

Disclosures: Astellas: Consultant or Advisor; Janssen: Consultant or Advisor; Wolters Kluwer: Health Publishing; McGraw Hill: Health Publishing; Merck Manual: Health Publishing; Canadian Journal of Urology   : Health Publishing; MDx Health: Consultant or Advisor; Merck Pharmaceuticals: Consultant or Advisor; Bayer: Consultant or Advisor; Strand laboratories: Consultant or Advisor

 

Heather Cheng, MD, PhD
Assistant Professor of Medical Oncology

University of Washington

Seattle, WA

Disclosures: Nothing to disclose.

 

 

Course 027IC: AUA CRPC Guidelines and Therapeutic Advances in Metastatic Prostate Cancer

Michael S. Cookson, MD, MMHC, Course Director

Professor and Chair, Department of Urology

University of Oklahoma

Oklahoma City, OK

Disclosures: TesoRx Pharma LLC : Consultant or Advisor; Janssen Biotech, Inc.: Consultant or Advisor; MDxHealth: Consultant or Advisor; Bayer Healthcare Pharmaceuticals: Consultant or Advisor; Tolmar: Consultant or Advisor; Myovant Sciences: Consultant or Advisor, Scientific Study or Trial; Merck: Consultant or Advisor; Janssen Scientific Affairs, LLC: Consultant or Advisor

 

David F. Jarrard, MD

Professor of Surgery and Molecular and Environmental Toxicology

University of Wisconsin

Madison, WI

Disclosures: Gregor Diagnostics: Consultant or Advisor

 

Adam S. Kibel, MD

Chief, Urologic Surgery, Brigham and Women’s Hospital

Chief, Urologic Surgery, Dana-Farber Cancer Institute

Professor, Department of Surgery, Harvard University School of Medicine

Chairman, Harvard Urology Residency Program

Co-Leader, Prostate Cancer Program, Dana-Farber/Harvard Cancer Center

Boston, MA

Disclosures: Profound: Consultant or Advisor; Janssen: Consultant or Advisor; ConfirmMDx: Consultant or Advisor; Bristol-Myers Squibb: Other; Merck: Consultant or Advisor

 

William T. Lowrance, MD, MPH

Associate Professor, Division of Urology, University of Utah School of Medicine

Investigator, Huntsman Cancer Institute (HCI)

Salt Lake City, UT

Disclosures: Myriad Genetics: Scientific Study or Trial; Stream Dx: Investment Interest

 

 

Course 037IC: Using Shared Decision Making to Help Patients Decide on Prostate Cancer Screening and Treatment

Danil V. Makarov, MD, Course Director

Assistant Professor, Department of Urology

Assistant Professor, Department of Population Health

Director, Surgical Research, Department of Population Health

New York University School of Medicine

New York, NY

Disclosures: Center for Devices and Radiological Health, United States Food and Drug Administration: Consultant or Advisor

 

Michael J. Barry, MD

Director, Informed Medical Decisions Program, Health Decision Sciences Center at MGH

Professor of Medicine, Harvard Medical School

Physician, Massachusetts General Hospital

Boston, MA

Disclosures: US Preventive Services Task Force: Consultant or Advisor; Healthwise: Scientific Study or Trial

 

Angela Fagerlin, MD

Chief, Department of Population Health Sciences

University of Utah School of Medicine

Salt Lake City, UT

Disclosures: Nothing to disclose.

 

 

Course 048IC: Novel Agents and Concepts in the Management of Hormone Naïve and CRPC

Judd W. Moul, MD, FACS, Course Director

James H. Semans, M.D. Professor of Urologic Surgery

Professor of Surgery

Professor in Anesthesiology

Duke University School of Medicine

Durham, NC

Disclosures: Sanofi-Aventis: Health Publishing, Meeting Participant or Lecturer; Theralogix: Consultant or Advisor; Janssen- J and J: Consultant or Advisor, Meeting Participant or Lecturer; Blue Earth Diagnostics: Consultant or Advisor, Scientific Study or Trial; Up to Date: Health Publishing; Best Doctors: Other

 

Lawrence I. Karsh, MD, FACS

Co-Founder and Attending Urologist, The Urology Center of Colorado

Director of Research, Advanced Therapeutics Clinic

Denver, CO

Disclosures: Astellas: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Dendreon: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Bayer: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Janssen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Genomic Health: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; EMD Serono: Consultant or Advisor; UROGPO: Consultant or Advisor; Genetech/Hoffman: Scientific Study or Trial; NeoGenomic Laboratories: Scientific Study or Trial; Arivan Research: Consultant or Advisor, Scientific Study or Trial; Nymox: Scientific Study or Trial; Urogen: Consultant or Advisor, Scientific Study or Trial; Siemans: Scientific Study or Trial; Arivan Research: Consultant or Advisor, Scientific Study or Trial; Myovant: Scientific Study or Trial; Cepheid: Scientific Study or Trial; Nucleix: Scientific Study or Trial; Minomic: Scientific Study or Trial; FKD: Scientific Study or Trial; Precision Biopsy               : Consultant or Advisor, Scientific Study or Trial; 3D Biopsy: Consultant or Advisor, Scientific Study or Trial; GenomeDx Biosciences: Consultant or Advisor, Scientific Study or Trial; Precision Med: Scientific Study or Trial; OPKO: Consultant or Advisor, Scientific Study or Trial; Vaxiion: Consultant or Advisor, Scientific Study or Trial; FKD: Scientific Study or Trial; Pfizer: Consultant or Advisor, Scientific Study or Trial; Ferring: Consultant or Advisor, Scientific Study or Trial; Abbvie: Consultant or Advisor; Astra-Zeneca: Consultant or Advisor; Augmenix: Consultant or Advisor, Scientific Study or Trial; Myriad Genetics: Consultant or Advisor, Scientific Study or Trial; Swan Valley Medical                : Consultant or Advisor, Investment Interest; Amgen: Consultant or Advisor, Scientific Study or Trial, Other; Heat Biologics: Scientific Study or Trial; MDxHealth: Scientific Study or Trial; Spectrum Pharmaceuticals: Consultant or Advisor, Scientific Study or Trial

 

Christopher Sweeney, MBBS

Professor, Medicine, Harvard Medical School

Medical Oncologist, Medical Oncology, Dana-Farber Cancer Institute

Boston, MA

Disclosures: Sanofi: Consultant or Advisor, Scientific Study or Trial; Janssen: Consultant or Advisor, Scientific Study or Trial; Astellas: Consultant or Advisor, Scientific Study or Trial; Bayer: Consultant or Advisor, Scientific Study or Trial; Genentech_Roche: Consultant or Advisor, Scientific Study or Trial

 

 

Course 065IC: Prostate Cancer Update

William J. Catalona, MD, Course Director

Professor of Urology

Northwestern University Feinberg School of Medicine

Chicago, IL

Disclosures: Beckman-Coulter Incorporated: Consultant or Advisor, Scientific Study or Trial; Beckman-Coulter Incorporated: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; deCODE genetics: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial

 

Stacy Loeb, MD

Assistant Professor, Department of Urology and Population Health

New York University

New York, NY

Disclosures: Lilly: Consultant or Advisor; Gilead: Investment Interest

 

Robert B. Nadler, MD

Professor, Department of Urology

Northwestern University

Chicago, IL

Disclosures: Allena: Scientific Study or Trial

 

Douglas M. Dahl, MD, FACS

Urologic Surgeon, Massachusetts General Hospital

Chief, Division of Urologic Oncology

Associate Professor of Urology

Harvard Medical School

Boston, MA

Disclosures: Amgen: Investment Interest; Pfizer: Investment Interest; C.R. Bard: Investment Interest; Abbott: Investment Interest; Johnson and Johnson: Investment Interest; Abbvie: Investment Interest; GlaxoSmithKline: Investment Interest; Merck: Investment Interest; Eli Lilly: Investment Interest; ExpressScripts: Investment Interest; Mylan: Investment Interest; Bristol Myers Squibb: Investment Interest

 

Russell Z.  Szmulewitz, MD

Associate Professor of Medicine, Section of Hematology/Oncology

Leader, Genitourinary Oncology Program

University of Chicago

Chicago, IL

Disclosures: Pfizer: Consultant or Advisor; Genentech: Scientific Study or Trial; Exelixis: Consultant or Advisor; Abbvie: Scientific Study or Trial; Incyte: Scientific Study or Trial; Astellas: Scientific Study or Trial

 

Stanley L. Liauw, MD

Associate Professor of Radiation Oncology

University of Chicago

Chicago, IL

Disclosures: Nothing to disclose.

 

Planners

Manoj Monga, MD, FACS

Director, Center for Endourology & Stone Disease

Cleveland Clinic

Cleveland, OH

Disclosures: Fortec: Other

 

Victor W. Nitti, MD

Professor of Urology and Obstetrics and Gynecology

Chair in Urology

Chief of Female Pelvic Medicine and Reconstructive Surgery (FPMRS)

David Geffen School of Medicine at UCLA

Los Angeles, CA

Disclosures: Serenity Pharmeuticals: Investment Interest

 

Michael Abern, MD

Assistant Professor, Urology

Director, Urologic Oncology

University of Illinois at Chicago

Chicago, IL

Disclosures:  Department of Defense Prostate Cancer Research Program: Scientific Study or Trial; American Urological Association Office of Education: Leadership Position

 

Estimated time to complete this activity: 1.25 hours

Release Date: October 2019

Expiration Date: October 31, 2020

Accreditation Statement

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The American Urological Association designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Content

This enduring material credit is valid only for content reformatted from courses 013IC, 027IC, 037IC, 048IC and 065IC.

Statement of Need

To better understand urologists’ educational needs for treating CRPC, the AUA conducted an in-depth educational needs assessment of its domestic membership representing >90% of U.S. Board Certified urologists in 2013 (Phase I). The AUA reassessed its member’s educational needs after releasing the updated CRPC Guideline and targeted CRPC educational activities in 2015 (Phase II) and again in 2017 (Phase III). Areas identified as an educational need with regard to managing CRPC patients center on sequencing of agents, managing side effects of treatments, management of comorbid conditions and identifying potential interactions between immunosuppressive agents and other medications. Urologists continue to indicate a strong educational need for a thorough review of the AUA CRPC Guideline.

 

Acknowledgements

The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

 

AbbVie

Amgen

Astellas

Genomic Health

Pfizer, Inc.

Sanofi Genzyme

 

American Urological Association Education & Research, Inc. ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1).

AUA Disclosure Policy

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual's relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Resolution of Identified Conflict of Interest

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Conflict of Interest Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

Evidence-Based Content

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous and free of commercial bias.

Off-label or Unapproved Use of Drugs or Devices

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Disclaimer

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Available Credit

  • 1.25 AMA PRA Category 1 Credit™
  • 1.25 Non-Physician Participation

Accreditation Period

Course opens: 
10/01/2019
Course expires: 
10/31/2020
Please login or register to take this course.